Portfolio and Partnership Companies:

 
BalinBac
ArKay
Creatv MicroTech
Claro Scientific
X-ela
NeoNur
 

 

Public Announcements of tTAp Participating Companies:


Aquarius acquired by Matinas BioPharma after Matinas raised approximately $20M

Aquarius Biotechnologies participated in the tTAp partnering with three potential CEOs. In the tTAp process, they were advised to focus on their lead compounds, and subsequently received an NIH grant to more their lead compound forward. They worked with one of them to develop and improve their messaging and presentation. Aquarius BioPharma’s lead compounds are now Matinas BioParmas’ lead compounds. See Aquarius in action at the tTAp

 


Wellesley Pharmaceuticals ~ $1M Raise

At the tTAp Wellesley revised their message and strategy to reach investors. Strengthening the delivery of their clinical potential of their compound combination, Wellesley partnered with a number of catalysts who help them connect with potential partners in Europe and the US. See Wellesley in action at the tTAp

 

endomedix-logo

– Endomedix receives a $1.5 M NIH Grant
– Endomedix selected as NIH featured at Bio 2015

Endomedix partnered with a catalyst with extensive experience in the hemostatic sealant market place at the tTAp. See Endomedics in action at the tTAp

 

LifeCuff

Raised $400,000 from a single investor
– LifeCuff as IRT Won NJTC Venture Fair Life Science Award

tTAp worked with IRT, or LifeCuff as it is now known, several times over the past year+. Refining their path and their needs, the tTAp advised LifeCuff on strategies to raise funds, and suggested potential avenues for growth. tTAp sponsored LifeCuff’s participation at the NJTC Venture Fair, and worked with them to prepare for the conference. See LifeCuff in action at the tTAp.

 

 

A sample of Participating Companies that took tTAp advice and reached a subsequent funding:

 
Silagene
Wellesley Pharma.
Symbiotic Health
Macroceutics
LifeCuff / IRT
LifeAire
Leading BioSciences
Guiding Technologies
GlycoMantra
Endomedix
Behavioral Instruments
Aquarius
Admera Health
FluidDA
Simphotek
allayasis
 

2014 results a (3)Starting with the beta class in 2014 – over 24% of each years participating companies have raised over $1M, or doubled revenue, each.

If you know of additional results, or are a tTAp company and would like to be considered for investor presentations, please contact us at results@techacceleration.us